Skip to content
Credit reportVerdict and grounds
Made on 21-11-2026 at 21:23
Reference CK-0436322331-20261121

ACE PHARMA

ActivePrivate limited company0436.322.331Grand'Route 289, 4347 Fexhe-le-Haut-Clocher
Retail sale of pharmaceutical products (NACE 47730) · founded in 1989 · 2 employees on 31-12-2025 · 4th oldest company in Fexhe-le-Haut-Clocher, Wholesale and retail trade sector · one director

Sources: the KBO register on 21-11-2026; the National Bank, 2025 annual accounts filed on 06-07-2026; the Belgian Official Gazette, latest deed of 15-04-2024.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,389 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€50,035
▲ 118% against 2024
Net result
€1,837
▼ 54.0% against 2024
Equity
€221,792
▲ 0.8% against 2024
Cash
€91,883
▲ 5.6% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, ACE PHARMA closed with a net profit of €1,837.Annual accounts 2025 page 2
  2. Equity stands at €221,792, or 76.6% of the balance sheet total of €289,661. The solvency of 76.6% is higher than at 85% of the 25,428 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
  3. The last five annual accounts came in on time. The 2025 accounts were filed 25 days before the end of the term.National Bank, filing of 06-07-2026 page 5

Representation

The signing rule is in the deed of 22-12-2023.

Articles of association, Belgian Official Gazette of 22-12-2023, deed 23472170

Ownership

holds 60% of the shares. Its equity stood at €66,954 on 31-12-2025. There is one other shareholder.

Annual accounts 2025 of

ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 1 of 6
ACE PHARMA0436.322.331 · report of 21-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin euro

202163,597202266,573202362,665202422,999202550,035202123,983202226,320202326,58220243,98920251,837
gross marginnet result

Equity and debtsin euro

20212022202320242025221,79267,870
equitydebts

Cashin euro

2021133,7672022171,8412023152,055202487,028202591,883
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€63,597€66,573€62,665€22,999€50,035
Operating result€34,983€38,515€35,783€6,556€4,343
Net result€23,983€26,320€26,582€3,989€1,837
Balance sheet at the closing date
Equity€233,664€229,184€215,966€219,955€221,792
Debts€63,934€93,809€90,571€61,821€67,870
Debts due after more than one year€847€0---
Debts due within one year€62,205€93,809€90,571€61,821€67,870
Cash€133,767€171,841€152,055€87,028€91,883
Balance sheet total€297,599€322,993€306,536€281,777€289,661
Operations
Employees in full-time equivalents1.01.01.00.12.0
Ratios
Solvency78.5%71.0%70.5%78.1%76.6%
Liquidity3.952.993.024.063.76

Source: Annual accounts 2025, micro format, filed on 06-07-2026 (2026-00257643); Annual accounts 2024, full format, filed on 03-07-2025 (2025-00240589); Annual accounts 2021 to 2023, filed from 24-06-2022 to 20-03-2024 (2022-20157565, 2023-00200099, 2024-00047248).

The operating result of 2025 is 34% lower than in 2024.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

ACE PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, rose from €22,999 to €50,035.

ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 2 of 6
ACE PHARMA0436.322.331 · report of 21-11-2026

Board, signature and ownership

Position on 21-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 22-12-2023.

Articles of association, Belgian Official Gazette of 22-12-2023, deed 23472170

Board

one director in office
Directorsince 05-03-2024
term without a fixed enddeed of 15-04-2024
Managing directorappointed by deed of 15-04-2024
term without a fixed enddeed of 15-04-2024

Ownership and group

Shareholders

holds 60% of the shares. Its equity stood at €66,954 on 31-12-2025. holds 40% of the shares. Its equity stood at €68,404 on 31-12-2025.

Annual accounts 2025 of , annual accounts 2025 of

Board changes

resigns. (managing director) and appointed. and act as permanent representatives. General meeting of 05-03-2024.

Gazette, deed 24060793

Company renamed from PHARMACIE MAQUOI to ACE PHARMA. changes role from manager to director. Discharge granted to . General meeting of 30-11-2023.

Gazette, deed 23472170
ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 3 of 6
ACE PHARMA0436.322.331 · report of 21-11-2026

Group

has 1 direct subsidiary (2025 accounts).

Country Company Equity Result
Belgium 1
BE ACE PHARMAthis company60% €221,792 result €1,837

Source: List of holdings in the 2025 accounts of . Every holding stands with its own latest accounts.

ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 4 of 6
ACE PHARMA0436.322.331 · report of 21-11-2026

Events and comparison

The latest events, newest first

Annual accounts 2025 filed, 25 days before the deadline.

NBB filing

Annual accounts 2024 filed, 28 days before the deadline.

NBB filing

Annual accounts 2023 filed, 133 days before the deadline.

NBB filing

Annual accounts 2022 filed, 28 days before the deadline.

NBB filing

Annual accounts 2021 filed, 37 days before the deadline.

NBB filing

Annual accounts 2020 filed, 54 days before the deadline.

NBB filing

Equity above €200,000. After 8 profitable years in a row, equity reaches €210,481.

Financial

Annual accounts 2019 filed, 23 days before the deadline.

NBB filing

Annual accounts 2018 filed, 57 days before the deadline.

NBB filing

Highest result from 2002 to 2025. The operating result of €55,120 and the net result of €41,134 are both a record.

Financial

Equity above €150,000. After 6 profitable years in a row, equity reaches €177,939.

Financial

Annual accounts 2017 filed, 46 days before the deadline.

NBB filing

Annual accounts 2016 filed, 48 days before the deadline.

NBB filing

Equity above €100,000. After 4 profitable years in a row, equity reaches €106,631.

Financial

Comparable companies, two years later

In July 2024, 17,048 companies had the same profile as ACE PHARMA has now: micro, 20 years or older, solvency 30% or more and a profit under 5% of the balance sheet. Two years later 94.3% were still trading, 5.2% had stopped another way and 0.6% had gone bankrupt.

still trading 94.3% stopped another way 5.2% bankrupt 0.6%

The return on assets of ACE PHARMA, 0.6%, is higher than at 37% of the 24,617 companies filing micro accounts in retail trade (NACE 47) in 2025.

Other findings

Peppol

Reachable for e-invoices since 07-08-2025, under 0208:0436322331.

Sanctions lists

Staff

2 employees on 31-12-2025, 0.6 full-time equivalents on average over the year.

ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 5 of 6
ACE PHARMA0436.322.331 · report of 21-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units21-11-2026KBO 0436.322.331
National Bank of BelgiumAnnual accounts 2025, micro format06-07-20262026-00257643
National Bank of BelgiumAnnual accounts 2024, full format03-07-20252025-00240589
National Bank of BelgiumAnnual accounts 2021 to 202324-06-2022 to 20-03-20242022-20157565, 2023-00200099, 2024-00047248
Belgian Official GazetteBoard15-04-2024deed 24060793
Belgian Official GazetteArticles of association with the signing rule22-12-2023deed 23472170
Peppol DirectoryRegistration for e-invoices07-08-20250208:0436322331
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies20-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

ACE PHARMA · 0436.322.331 · credit report of 21-11-2026Page 6 of 6